Immunotherapies for Parkinson's disease: Progression of Clinical Development

CNS Neurol Disord Drug Targets. 2021 May 26. doi: 10.2174/1871527320666210526160926. Online ahead of print.ABSTRACTParkinson's disease is a common neurodegenerative disease affecting the movement and wellbeing of most elderlies. The manifestations of Parkinson's disease often include resting tremor, stiffness, bradykinesia and muscular rigidity. The typical hallmark of Parkinson's disease is the destruction of neurons in the substantia nigra and the presence of Lewy bodies in different compartments of the central nervous system. Due to various limitations to the currently available treatments, immunotherapies have emerged to be the new approach to Parkinson's disease treatment. This approach shows some positive outcomes on the efficacy in removing the aggregated species of alpha-synuclein, which is believed to be one of the causes of Parkinson's disease. In this review, an overview of how alpha-synuclein contributes to Parkinson's disease and the effects of a few new immunotherapeutic treatments, including BIIB054 (cinpanemab), MEDI1341, AFFITOPE and PRX002 (prasinezumab) that are currently under clinical development, will be discussed.PMID:34042040 | DOI:10.2174/1871527320666210526160926
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Source Type: research